Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.45 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.42 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.42 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.41 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15133363 | 0.91 | FABP3 (0.46) | FABP3PLA2G2CENPP2P2RY10GPR34 | |
| SCHEMBL15161266 | 0.89 | PLA2G2C (0.46) | FABP3PLA2G2CENPP2P2RY10GPR34 | |
| SCHEMBL19354801 | 0.87 | LPAR1 (0.44) | FABP3PLA2G2CP2RY10GPR34LPAR1 | |
| SCHEMBL15942985 | 0.87 | LPAR1 (0.44) | FABP3PLA2G2CP2RY10GPR34LPAR1 | |
| SCHEMBL15161242 | 0.87 | FABP3 (0.55) | FABP3P2RY10GPR34 | |
| SCHEMBL19354790 | 0.86 | LPAR1 (0.46) | FABP3PLA2G2CP2RY10GPR34LPAR1 | |
| SCHEMBL18164945 | 0.82 | FABP3 (0.35) | FABP3ENPP2P2RY10GPR34PLA2G2A | |
| SCHEMBL8797728 | 0.81 | TSHR (0.48) | LPAR1LPAR3LPAR6LPAR4LPAR5 | |
| SCHEMBL13271118 | 0.80 | FABP3 (0.64) | FABP3ENPP2LPAR1LPAR3LPAR6 | |
| SCHEMBL12348817 | 0.79 | PLA2G2C (0.64) | FABP3PLA2G2CENPP2P2RY10GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | disclosed |
| US-9566288-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-02-14 | — | — | US | disclosed |
| US-20150216882-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-9006217-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-04-14 | — | — | US | disclosed |
| US-8802875-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-08-12 | — | — | US | disclosed |
| US-8759557-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| US-8569529-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-10-29 | — | — | US | disclosed |
| US-20130237720-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-09-12 | — | — | US | disclosed |
| US-20130158283-A1 | Process for the Preparation of Oxidized Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216882-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | FABP3 478/4885PLA2G2C 13/4885ENPP2 50/4885 |
| US-20130158283-A1 | Process for the Preparation of Oxidized Phospholipids | PHOSPHO1, SGMS1, SGMS2 | FABP3 1014/4885PLA2G2C 19/4885ENPP2 106/4885 |
| US-20170246197-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | FABP3 478/4885PLA2G2C 13/4885ENPP2 50/4885 |
| US-20130237720-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | FABP3 478/4885PLA2G2C 13/4885ENPP2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.